SensNews Sept 2020

Sensor100 September 2020 18 Quotient Gains FDA EUA for Covid-19 Antibody Test Quotient Limited headquartered in Eysins, Switzerland, announced that on Septem- ber 25, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19 antibody test.The test detects anti- bodies generated in humans in response to the SARS-CoV-2 virus using Quotient's proprietary MosaiQ blood testing microarray technology.The anti- body test was CE marked on May 1, 2020 and is now available in Europe and the US. As previously announced, Quotient has entered into contracts to supply its COVID-19 antibody tests to customers in the U.S. One of those customers, Bloodworks Northwest, is seeking to source convalescent blood plasma taken from donors whose blood contains SARS-CoV-2 virus antibodies, for use in treating COVID-19 patients. Quotient believes customers find its COVID-19 antibody tests attractive because they are highly accurate and the MosaiQ system is efficient. The test is performed on Quotient's fully automated, high-through- put MosaiQ instrument. A single MosaiQ testing instrument can process up to 3,000 antibody tests per day. Quotient Press Release 28 September The innovative technology that allowed Quotient to create the MosaiQ COVID-19 Antibody Microarray is powered by the proprietary MosaiQ Reaction that delivers fast, accurate results every 24 seconds on the MosaiQ system – a multiplexing, multimodal solution for central laboratories.